Methyl homoveratrate
CAS No. 15964-79-1
Methyl homoveratrate( —— )
Catalog No. M26295 CAS No. 15964-79-1
Methyl homoveratrate is a metabolite of McN5691 in plasma, urine and faecal extract. McN5691 is a voltage-sensitive calcium channel blocker.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 100MG | 35 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 82 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMethyl homoveratrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionMethyl homoveratrate is a metabolite of McN5691 in plasma, urine and faecal extract. McN5691 is a voltage-sensitive calcium channel blocker.
-
DescriptionMethyl homoveratrate is a metabolite of McN5691 in plasma, urine and faecal extract. McN5691 is a voltage-sensitive calcium channel blocker.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number15964-79-1
-
Formula Weight210.229
-
Molecular FormulaC11H14O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (475.67 mM)
-
SMILESCOC(=O)Cc1ccc(OC)c(OC)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Van Scoy AR, Tjeerdema RS. Environmental fate and toxicology of clomazone. Rev Environ Contam Toxicol. 2014;229:35-49.
molnova catalog
related products
-
Butyrospermol
Butyrospermol is a protolimonoid extracted from shea (Euphorbia). As a long-chain fatty acid ester first discovered from natural products, Butyrospermol has antifeedant and antitumor activities.
-
Xylotetraose
Xylotetraose is a hydrolysis product of Xylan. Xylan is a polysaccharide made from units of xylose and contains predominantly β-D-xylose units linked as in cellulose.
-
Taccalonolide AJ
Taccalonolide AJ is a microtubule stabilizer; it has excellent and highly persistent antitumor efficacy when administered directly to the tumor, suggesting that the lack of antitumor efficacy seen with systemic administration of AJ is likely due to its short half-life in vivo.
Cart
sales@molnova.com